| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Oteracil potassium targets multiple enzymes. It is a selective competitive inhibitor of uricase (urate oxidase). It also inhibits orotate phosphoribosyltransferase (OPRT), an enzyme involved in the activation of 5-fluorouracil (5-FU). By inhibiting OPRT, it reduces the conversion of 5-FU to its active form, FUMP, thereby decreasing 5-FU's gastrointestinal toxicity. This modulation of 5-FU metabolism is its primary therapeutic mechanism.
|
|---|---|
| ln Vitro |
In vitro, oteracil potassium acts as an inhibitor of orotate phosphoribosyltransferase. This inhibition reduces the formation of the active metabolite of 5-fluorouracil, FUMP, thereby decreasing the drug's cytotoxic effects. It is also a competitive inhibitor of uricase. These biochemical activities contribute to its pharmacological effects.
|
| ln Vivo |
Potassium oxonate can be utilized in animal modeling to produce a high uric acid model.
Oteracil potassium is used in vivo as an adjunct to 5-fluorouracil-based chemotherapy to reduce gastrointestinal toxicity. It is available in combination with gimeracil and tegafur in the commercially available product Teysuno. By inhibiting OPRT in the gastrointestinal tract, it reduces the activation of 5-FU in these tissues, sparing them from the drug's toxic effects while allowing the drug to be activated in tumor tissues. |
| Enzyme Assay |
Oteracil potassium is evaluated in cell-free enzymatic assays to measure its inhibition of orotate phosphoribosyltransferase (OPRT). The compound is incubated with OPRT and its substrates, and the inhibition of enzyme activity is measured. Its ability to inhibit uricase can also be assessed in cell-free assays. These assays help to confirm its mechanism of action.
|
| Cell Assay |
Oteracil potassium is assessed in cell-based assays to study its effects on 5-FU metabolism and toxicity. Cells are treated with 5-FU in the presence and absence of oteracil potassium, and the formation of FUMP and other metabolites is measured. The compound's ability to reduce 5-FU-induced cytotoxicity is evaluated in relevant cell lines, particularly those of gastrointestinal origin.
|
| Animal Protocol |
Oteracil potassium is administered orally in animal models and in clinical settings to evaluate its ability to modulate 5-FU toxicity. It is used in combination with tegafur and gimeracil. In animal models, its efficacy is assessed by measuring the levels of 5-FU metabolites in tissues and by evaluating gastrointestinal toxicity. Its ability to induce hyperuricemia by inhibiting uricase is also studied in rodents.
|
| ADME/Pharmacokinetics |
Oteracil potassium has a molecular formula of C4H2KN3O4 and a molecular weight of 195.17. Its CAS number is 2207-75-2. The compound is a white to off-white solid. It is soluble in water. It should be stored under recommended conditions. It is also known as potassium oxonate and oxonic acid potassium salt.
|
| Toxicity/Toxicokinetics |
Oteracil potassium is generally well-tolerated when used as part of combination therapy. It can cause hyperuricemia due to its inhibition of uricase. It is for therapeutic use and is available by prescription only. Its safety profile has been established in clinical trials.
|
| References |
|
| Additional Infomation |
Potassium 2,6-dihydroxytriazine carboxylate is an organic molecular entity. Oteeracil potassium is the potassium salt of potassium oxyacid, an enzyme inhibitor that modulates the toxicity of 5-fluorouracil (5-FU). Potassium oxyacid inhibits orotate phosphoribosyltransferase, an enzyme that catalyzes the conversion of 5-FU to its active or phosphorylated form, FUMP. After oral administration, potassium oxyacid selectively distributes intracellularly to the cells of the small intestinal wall, producing a local inhibitory effect in the gastrointestinal tract. Therefore, 5-FU-related gastrointestinal toxicity is reduced, and the incidence of diarrhea or mucositis during 5-FU-related treatment is decreased.
Oteracil potassium is the potassium salt of oxonate. It is a selective competitive inhibitor of uricase. It is used as an adjunct to antineoplastic therapy to reduce the toxic side effects of 5-fluorouracil. It is a component of the drug product Teysuno. It is a therapeutic agent. |
| Molecular Formula |
C4H2KN3O4
|
|---|---|
| Molecular Weight |
195.18
|
| Exact Mass |
194.968
|
| CAS # |
2207-75-2
|
| PubChem CID |
2723920
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
300 °C(lit.)
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
274
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IAPCTXZQXAVYNG-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C4H3N3O4.K/c8-2(9)1-5-3(10)7-4(11)6-1;/h(H,8,9)(H2,5,6,7,10,11);/q;+1/p-1
|
| Chemical Name |
potassium;4,6-dioxo-1H-1,3,5-triazine-2-carboxylate
|
| Synonyms |
Oxonate, potassium; Oxonic acid potassium salt; Oteracil potassium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~3.33 mg/mL (~17.06 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 9.09 mg/mL (46.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
Solubility in Formulation 2: 5 mg/mL (25.62 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with heating and sonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1235 mL | 25.6174 mL | 51.2348 mL | |
| 5 mM | 1.0247 mL | 5.1235 mL | 10.2470 mL | |
| 10 mM | 0.5123 mL | 2.5617 mL | 5.1235 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
None
CTID: jRCT2080220727
Phase: Status:
Date: 2009-04-30
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
